{"id":167429,"date":"2010-01-11T20:38:35","date_gmt":"2010-01-12T01:38:35","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=58169"},"modified":"2010-01-11T20:38:35","modified_gmt":"2010-01-12T01:38:35","slug":"zymogenetics-closes-90m-deal","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/167429","title":{"rendered":"ZymoGenetics Closes $90M Deal"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/finances\/\">Finances<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>ZymoGenetics, the Seattle-based biotech company, <a href=\"http:\/\/finance.yahoo.com\/news\/ZymoGenetics-Announces-Full-bw-1016636210.html?x=0&amp;.v=1\">said today<\/a> its underwriters have exercised their options to buy all the shares they were granted, bringing its net proceeds from the latest offering to $90.9 million. Investors and underwriters bought a total of 16.1 million shares at $6 apiece, ZymoGenetics said. The money will be used to support R&amp;D, and to help market the company&#8217;s lone approved drug, recombinant thrombin (Recothrom).<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/01\/11\/zymogenetics-closes-90m-deal\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20ZymoGenetics%20Closes%20$90M%20Deal%20http:\/\/xconomy.com\/?p=58169\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/01\/11\/zymogenetics-closes-90m-deal\/&#038;t=ZymoGenetics%20Closes%20$90M%20Deal\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/01\/11\/zymogenetics-closes-90m-deal\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=ZymoGenetics+Closes+%2490M+Deal&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F01%2F11%2Fzymogenetics-closes-90m-deal%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=91e3239a132ce6dc1dde7b911ede8b08&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=91e3239a132ce6dc1dde7b911ede8b08&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/aJLDa1ve7OqAnQgTFplCPLbYJng\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/aJLDa1ve7OqAnQgTFplCPLbYJng\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/aJLDa1ve7OqAnQgTFplCPLbYJng\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/aJLDa1ve7OqAnQgTFplCPLbYJng\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/DQgoiAbmizw\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Finances, deals Luke Timmerman wrote: ZymoGenetics, the Seattle-based biotech company, said today its underwriters have exercised their options to buy all the shares they were granted, bringing its net proceeds from the latest offering to $90.9 million. Investors and underwriters bought a total of 16.1 million shares at $6 apiece, ZymoGenetics said. The money [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-167429","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/167429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=167429"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/167429\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=167429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=167429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=167429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}